Mode
Text Size
Log in / Sign up
N/A Completed N=634

Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710

Source: ClinicalTrials.gov NCT02756637 ↗
Enrolled (actual)
634
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcomePrimary: Overall Survival — 58; 58 participants

Summary

The purpose of this study is to perform a secondary analysis of SWOG 8710 to assess NLRs value as a biomarker. Specifically, the investigators test two hypotheses: 1) that baseline NLR is correlated with overall survival after curative treatment for BC and 2) that baseline NLR is correlated with the survival benefit of NAC. The study will look at the data from participants of the SWOG 8710 study.

Outcome Measures

OutcomeResultp-value
PRIMARY
Overall Survival
58; 58 —

Eligibility Criteria

Inclusion Criteria

  • SWOG 8710 original trial inclusion criteria included:
  • Node-negative, muscle-invasive transitional cell carcinoma of the bladder, T2-T4aN0M0 per the AJCC 4th edition staging manual.
  • SWOG performance status of 0 or 1
  • Adequate organ function by lab criteria (WBC > 4,000 cells/mm3, platelets >150,000 cells/mm3, creatinine <1.5 md/dL (men) or <1.3 md/dL (women), baseline liver tests < 2 times normal limits)
  • Inclusion criteria for this secondary analysis are:
  • Eligible for original SWOG 8710 trial
  • Had complete blood count with differential prior to first treatment (radical cystectomy or NAC).

Exclusion Criteria

  • SWOG 8710 original trial exclusion criteria included:
  • No age restrictions
  • Previous or concomitant malignancy other than bladder cancer or basal cell skin cancer
  • Prior pelvic radiation
  • Metastatic or incurable disease
  • Laboratory values exceeding those detailed in 3.1.c
  • Exclusion criteria for this secondary analysis are:
  • Ineligibility for the original SWOG 8710 study
  • Lack of complete blood count with differential prior to first treatment (cystectomy or NAC).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02756637). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search